TrialNature communications2025

Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.

Andreas Papagiannis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.